日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy-phase II investigator-initiated trial (NCCH2412/MK015)

ENVELOPE:恩福妥单抗治疗对铂类药物难治或不耐受的晚期小肠腺癌患者——II期研究者发起试验(NCCH2412/MK015)

Fujii, H; Hirano, H; Kudo, T; Tsuchihashi, K; Shoji, H; Okita, N; Hirose, T; Takashima, A; Yokoyama, M; Kawasaki, M; Shuda, Y; Naito, M; Ichikawa, K; Sekine, K; Sato, J; Yamamoto, N; Kato, K

Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis

探索小肠腺癌的新型治疗靶点:来自 Claudin 18.2、Nectin-4 和 HER3 表达分析的启示

Fujii, H; Shoji, H; Hirano, H; Hirose, T; Okita, N; Takashima, A; Kato, K

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

帕博利珠单抗联合化疗对比单纯化疗治疗晚期食管癌:一项随机III期KEYNOTE-590研究的5年延长随访结果

Metges, J-P; Kato, K; Sun, J-M; Shen, L; Enzinger, P C; Adenis, A; Doi, T; Kojima, T; Li, Z; Kim, S-B; Cho, B C; Mansoor, W; Li, S-H; Sunpaweravong, P; Alsina, M; Buchschacher, G L Jr; Hara, H; Tsuji, A; Wu, J; Shah, S; Bhagia, P; Shah, M A

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213

一线顺铂化疗治疗晚期消化道神经内分泌癌患者总生存期的预后因素:JCOG1213 的一项事后分析

Hirano, H; Hirata, K; Honma, Y; Morizane, C; Machida, N; Kato, K; Okusaka, T; Boku, N; Sekine, S; Hiraoka, N; Mizusawa, J; Sano, Y; Shibuya, Y; Takahashi, M; Fujimori, N; Nomura, M; Doki, Y; Ueno, M; Yoshikawa, T; Takeuchi, H

Family views on health resources and services in the intermountain west: a qualitative study

美国西部山区家庭对医疗资源和服务的看法:一项定性研究

Castaneda, Gladys Lopez; Hoy, Mariah P; Haupeakui, Kato K; Jarman, Halle M; Chaney, Robert A; Magnusson, Brianna M; Crandall, AliceAnn

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

Tislelizumab 与化疗作为欧洲和北美晚期或转移性食管鳞状细胞癌患者二线治疗的比较:一项随机 III 期 RATIONALE-302 研究的亚组分析

Ajani, J; El Hajbi, F; Cunningham, D; Alsina, M; Thuss-Patience, P; Scagliotti, G V; Van den Eynde, M; Kim, S-B; Kato, K; Shen, L; Li, L; Ding, N; Shi, J; Barnes, G; Van Cutsem, E

Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups

免疫检查点抑制剂在晚期胃食管腺癌中的应用:不同程序性死亡配体1亚组的患者水平荟萃分析

Leone, A G; Mai, A S; Fong, K Y; Yap, D W T; Kato, K; Smyth, E; Moehler, M; Seong, J T C; Sundar, R; Zhao, J J; Pietrantonio, F

Novel Functional Peptide for Next-Generation Vital Pulp Therapy

用于下一代活髓治疗的新型功能肽

M Watanabe, M Okamoto, S Komichi, H Huang, S Matsumoto, K Moriyama, J Ohshima, S Abe, M Morita, M Ali, K Takebe, I Kozaki, A Fujimoto, K Kanie, R Kato, K Uto, M Ebara, A Yamawaki-Ogata, Y Narita, Y Takahashi, M Hayashi

Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis

PD-L1和PD-L2表达与BRAF V600E突变转移性结直肠癌中肿瘤浸润淋巴细胞的相关性:GI-SCREEN事后分析

Imai, M; Nakamura, Y; Denda, T; Komatsu, Y; Yuki, S; Nishina, T; Hamamoto, Y; Hara, H; Esaki, T; Kawakami, H; Kato, K; Satoh, T; Okano, N; Sunakawa, Y; Taniguchi, H; Yamaguchi, K; Yamada, T; Miki, I; Wakabayashi, M; Kuwata, T; Shitara, K; Yoshino, T

Structural snapshots of V/A-ATPase reveal the rotary catalytic mechanism of rotary ATPases

V/A-ATPase的结构快照揭示了旋转ATPase的旋转催化机制

J Kishikawa #, A Nakanishi #, A Nakano #, S Saeki, A Furuta, T Kato, K Mistuoka, K Yokoyama